Brief: Savara Announces Molgramostim Nebulizer Solution Achieved Statistical Significance For Primary Endpoint

Savara

26/06/2024 11:38

June 26 (Reuters) - Savara Inc  SVRA.O :
    * SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION
(MOLGRAMOSTIM)
ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND
MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3
CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
(APAP)
    * SAVARA INC: PLANS TO COMPLETE BLA SUBMISSION IN 1H 2025
    * SAVARA INC: ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY
ENDPOINT

Source text for Eikon:  ID:nBw5WjvGpa 
Further company coverage:  SVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))